JPWO2021228987A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021228987A5 JPWO2021228987A5 JP2022568518A JP2022568518A JPWO2021228987A5 JP WO2021228987 A5 JPWO2021228987 A5 JP WO2021228987A5 JP 2022568518 A JP2022568518 A JP 2022568518A JP 2022568518 A JP2022568518 A JP 2022568518A JP WO2021228987 A5 JPWO2021228987 A5 JP WO2021228987A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical product
- ttr
- antibody
- designed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20174177.4 | 2020-05-12 | ||
| EP20174177 | 2020-05-12 | ||
| PCT/EP2021/062706 WO2021228987A1 (en) | 2020-05-12 | 2021-05-12 | Combination therapy for ttr amyloidosis |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023525790A JP2023525790A (ja) | 2023-06-19 |
| JP2023525790A5 JP2023525790A5 (https=) | 2024-05-23 |
| JPWO2021228987A5 true JPWO2021228987A5 (https=) | 2024-05-23 |
| JP7834032B2 JP7834032B2 (ja) | 2026-03-23 |
Family
ID=70682637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568518A Active JP7834032B2 (ja) | 2020-05-12 | 2021-05-12 | Ｔｔｒアミロイドーシスに対する併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230183329A1 (https=) |
| EP (1) | EP4149972A1 (https=) |
| JP (1) | JP7834032B2 (https=) |
| KR (1) | KR20230009950A (https=) |
| CN (1) | CN115551886A (https=) |
| AU (1) | AU2021272369A1 (https=) |
| BR (1) | BR112022023031A2 (https=) |
| CA (1) | CA3172824A1 (https=) |
| CL (2) | CL2022003141A1 (https=) |
| CO (1) | CO2022017877A2 (https=) |
| IL (1) | IL298135A (https=) |
| MX (1) | MX2022014223A (https=) |
| WO (1) | WO2021228987A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023099788A1 (en) * | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| AU2023382527A1 (en) * | 2022-11-15 | 2025-06-26 | Alexion Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2025104243A1 (en) | 2023-11-15 | 2025-05-22 | Neurimmune Ag | Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2025238147A1 (en) * | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| US10344080B2 (en) * | 2013-12-20 | 2019-07-09 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor |
| EP3101131B1 (en) | 2014-01-29 | 2020-08-19 | KM Biologics Co., Ltd. | Anti-transthyretin humanized antibody |
| EP3981874A1 (en) | 2014-01-29 | 2022-04-13 | KM Biologics Co., Ltd. | Anti-transthyretin human antibody |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2018007923A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| CU24731B1 (es) * | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| CU20200042A7 (es) * | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
-
2021
- 2021-05-12 CN CN202180034796.0A patent/CN115551886A/zh active Pending
- 2021-05-12 AU AU2021272369A patent/AU2021272369A1/en active Pending
- 2021-05-12 MX MX2022014223A patent/MX2022014223A/es unknown
- 2021-05-12 WO PCT/EP2021/062706 patent/WO2021228987A1/en not_active Ceased
- 2021-05-12 JP JP2022568518A patent/JP7834032B2/ja active Active
- 2021-05-12 CA CA3172824A patent/CA3172824A1/en active Pending
- 2021-05-12 BR BR112022023031A patent/BR112022023031A2/pt unknown
- 2021-05-12 US US17/924,496 patent/US20230183329A1/en active Pending
- 2021-05-12 EP EP21724330.2A patent/EP4149972A1/en active Pending
- 2021-05-12 IL IL298135A patent/IL298135A/en unknown
- 2021-05-12 KR KR1020227043263A patent/KR20230009950A/ko active Pending
-
2022
- 2022-11-10 CL CL2022003141A patent/CL2022003141A1/es unknown
- 2022-12-09 CO CONC2022/0017877A patent/CO2022017877A2/es unknown
-
2025
- 2025-04-14 CL CL2025001129A patent/CL2025001129A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1853310B1 (en) | Anti a beta antibody formulation | |
| AU2001272956B8 (en) | Treatment of central nervous system diseases by antibodies against glatiramer acetate | |
| JP2020143115A (ja) | 片頭痛の治療または予防法 | |
| CN114173816A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| MX2011002159A (es) | Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria. | |
| CN115427450A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| JP2020100653A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| CN107073110A (zh) | 使用il‑17拮抗剂抑制银屑病关节炎患者的结构损伤进展 | |
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| WO2021255621A1 (en) | Treatment of food allergy using anti-ige antibodies | |
| JPWO2021228987A5 (https=) | ||
| JP7798763B2 (ja) | Ｃ５関連疾患の治療または予防のための投与レジメン | |
| AU2021293980B2 (en) | Treatment of food allergy using anti-IgE antibodies | |
| KR20250011948A (ko) | 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법 | |
| JP2024534004A (ja) | 抗トリプターゼ抗体のための投与量 | |
| US20230235041A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| EA046525B1 (ru) | Система и способ контроля таблеток ядерного топлива | |
| IL317086A (en) | Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists | |
| WO2021111377A2 (en) | Methods of treating lichen planus using interleukin-17 (il-17) antagonists | |
| HK1163504A (en) | Anti a beta antibody formulation | |
| HK1108132B (en) | Anti a beta antibody formulation | |
| JPWO2020185750A5 (https=) |